Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Bristol-Myers to stop new antiviral drug research

Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs.

Published
26 June 2015
From
Reuters
China rejects Gilead hepatitis C drug patent: advocacy group

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

Published
19 June 2015
From
Reuters
Don’t Weaken the F.D.A.’s Drug Approval Process

The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk of injury or death. While the legislation does not mandate this approach, it opens the door to it.

Published
12 June 2015
From
New York Times
Trans-Pacific Partnership Transparency for the Big Pharma Wrecking Crew

A new WikiLeak release of the recent draft text of the US-led proposal for the Trans-Pacific Partnership annex on Pharmaceuticals and Medical Devices shows how the fig-leaf of “transparency” and “procedural fairness” is being used to allow transnational pharmaceutical companies to subvert countries’ ability to make decisions about which drugs and medical devices they can afford to cover, in order to expand access for monopoly-priced medicines.

Published
12 June 2015
From
Health Gap
U.S. Shifts Stance on Drug Pricing in Pacific Trade Pact Talks, Document Reveals

Facing resistance from Pacific trading partners, the Obama administration is no longer demanding protection for pharmaceutical prices under the 12-nation Trans-Pacific Partnership, according to a newly leaked section of the proposed trade accord.

Published
12 June 2015
From
New York Times
The Medicines Patent Pool and Gilead Sciences Expand Licence to Allow Generic Manufacture of Medicines in South Africa

The Medicines Patent Pool (MPP) announced an expansion of its current licensing agreement with Gilead Sciences for generic manufacture of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF) and other Gilead medicines. The amendment enhances MPP’s current licence by allowing South African manufacturers to join Indian and Chinese companies in developing generics for low- and middle-income countries.

Published
12 June 2015
From
Medicines Patent Pool
Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure

The company selling a costly breakthrough to millions of hepatitis C sufferers thinks price is the wrong thing to talk about.

Published
09 June 2015
From
Bloomberg
Campaign for Affordable Medicine Gains Ground in South Africa

Patient and leading health organisations in South Africa have now joined a Fix the Patent Laws campaign launched in 2011 by Treatment Action Campaign (TAC) and Doctors Without Borders (MSF) to push for reform of the country’s current patent laws.

Published
03 June 2015
From
Inter Press Service
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide (F/TAF) for HIV Treatment

Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application (MAA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). - See more at: http://www.gilead.com/news/press-releases/2015/5/european-medicines-agency-validates-gileads-marketing-application-for-fixeddose-combination-of-emtricitabine-and-tenofovir-alafenamide-for-hiv-treatment?#sthash.jLacUtX1.dpuf

Published
02 June 2015
From
Gilead
Panel: Compulsory licensing could address high-priced medicines in Europe

The high prices of medicine, which affects access to affordable medicine, was a theme of the annual World Health Assembly over the past week. In one side event, a panel discussed compulsory licensing as a vehicle to be used in combatting the high prices of medicine, not only in developing countries, but in Europe.

Published
29 May 2015
From
Intellectual Property Watch
← First12345...78Next →

Filter by country